Key facts
- This page summarizes Daniel E. Geffken's Form 4 filing for ProMIS Neurosciences Inc. (PMN).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 30 Oct 2023, 19:42.
Daniel E. Geffken - 26 Oct 2023 Form 4 Insider Report for ProMIS Neurosciences Inc. (PMN)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- PMN
- Reported as of
- 26 Oct 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 30 Oct 2023, 19:42:08 UTC
- Prior SEC filing
- 29 Aug 2023
- Next SEC filing
- 16 Feb 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Max A. Milbury Attorney-in-Fact for Daniel E. Geffken
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Daniel E. Geffken filed Form 4 for ProMIS Neurosciences Inc. (PMN) on 30 Oct 2023.
Change
- Previous filing in this sequence was filed on 29 Aug 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PMN
transaction
Derivative
Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +2,500
- Change %
- Price
- $0.000000
- Shares after
- 2,500
- Date
- 26 Oct 2023
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 2,500
- Exercise price
- $1.87
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
25% of the shares subject to this option shall vest on October 26, 2024, and the balance shall vest ratably over 36 months.